Clinical Trial Search

Primary: Percentage of Participants Who Achieved Low Disease Activity (LDA) (Clinical Disease Activity Index [CDAI] <=10) at 6 Months: by Overall Tofa Initiators, Monotherapy and…

Primary: Change From Baseline Percent Drinking Days Per Month at Immediate Post-Treatment — -20.00; -11.11 percent drinking days per month — p=.838

Primary: Average Left-Ventricular Wall Thickness-Dimension Ratio Z-score (LVWT/Dz) — -0.1372; -0.0893; -0.2167; 0.3215 z-score — p=0.15

Primary: Safety as Evaluated by Rate and Severity of Treatment-emergent AEs (TEAEs) — 1; 0; 0; 0 Participants

Primary: Change From Baseline to Week 26 in Glycated Haemoglobin (HbA1c) (%) — -0.8; -1.3; -1.6; -0.7 Percentage point of HbA1C — p=0.0078

Primary: Geometric Mean Titers (GMTs) of Influenza Vaccine Antibodies at Day 1- Per Protocol Analysis Set (PPAS) — 30.8; 38.9; 50.1; 47.5 titers

Primary: Average Improvement in VAS Pain Score From Baseline to Day 7 — 2.2 score on a scale

Primary: Need for Dialysis in the First 30 Days Post-transplant — 10; 10 Participants

Primary: Change From Baseline in the Modified UMSARS Score at Week 48 — 5.20; 4.85 units on a scale — p=0.4656

Primary: Number of Participants With Treatment-emergent Adverse Events (AEs) — 139; 0; 6; 6 Participants

Primary: Medline 2% CHG Cloth Dosage of Coverage Area — 0.0081 g/cm^2

Primary: Change in PGC-1alpha RNA Expression — -0.02190716; 0.3160562; 0.07414876; 0.4800263 Log 2 fold change

Primary: Change From Baseline in Pain Scores on Postoperative Day 2, as Measured by the Wong-Baker 0-to-10 Pain Scale — 2.1; 2.4 score on a scale — p=0.69

Primary: Adolescent Feasibility of Intervention — 4.5; 4.7 score on a scale

Primary: COPD Assessment Test (CAT) — 22.0; 21.9; 21.5; 22.7 score on a scale